| Some Selected Abstracts: | |
|
1. |
1.
Cummings DA, Schwartz IB, Billings L, Shaw LB, Burke DS. Dynamic
effects of antibody-dependent enhancement on the fitness of viruses. Proc
Natl Acad Sci U S A. 2005 Oct 18;102(42):15259-64.
Department of International Health, Bloomberg
School of Public Health, The Johns Hopkins University, 615 North Wolfe
Street, Baltimore, MD 21205, USA. Antibody-dependent enhancement (ADE), a phenomenon in which viral replication is increased rather than decreased by immune sera, has been observed in vitro for a large number of viruses of public health importance, including flaviviruses, coronaviruses, and retroviruses. The most striking in vivo example of ADE in humans is dengue hemorrhagic fever, a disease in which ADE is thought to increase the severity of clinical manifestations of dengue virus infection by increasing virus replication. We examine the epidemiological impact of ADE on the prevalence and persistence of viral serotypes. Using a dynamical system model of n cocirculating dengue serotypes, we find that ADE may provide a competitive advantage to those serotypes that undergo enhancement compared with those that do not, and that this advantage increases with increasing numbers of cocirculating serotypes. Paradoxically, there are limits to the selective advantage provided by increasing levels of ADE, because greater levels of enhancement induce large amplitude oscillations in incidence of all dengue virus infections, threatening the persistence of both the enhanced and non enhanced serotypes. Although the models presented here are specifically designed for dengue, our results are applicable to any epidemiological system in which partial immunity increases pathogen replication rates. Our results suggest that enhancement is most advantageous in settings where multiple serotypes circulate and where a large host population is available to support pathogen persistence during the deep troughs of ADE-induced large amplitude oscillations of virus replication. |
|
Diagnosis, Diagnostics,
Immunodiagnosis & Immunodiagnostics: |
|
13745.
Basilio-de-Oliveira
CA, Aguiar GR, Baldanza MS, Barth OM, Eyer-Silva WA, Paes MV. Pathologic
study of a fatal case of dengue-3 virus infection in Rio de Janeiro,
Brazil. Braz J Infect Dis. 2005 Aug;9(4):341-7. 13746.
Bruce MG,
Sanders EJ, Leake JA, Zaidel O, Bragg SL, Aye T, Shutt KA, Deseda CC,
Rigau-Perez JG, Tappero JW, Perkins BA, Spiegel RA, Ashford DA.
Leptospirosis among patients presenting with dengue-like illness in
Puerto Rico. Acta Trop. 2005 Oct;96(1):36-46. 13747.
Chutinimitkul
S, Payungporn S, Theamboonlers A, Poovorawan Y. Dengue typing assay
based on real-time PCR using SYBR Green I. J Virol Methods. 2005
Oct;129(1):8-15. 13748. Matheus S, Deparis X, Labeau B, Lelarge J, Morvan J, Dussart P. Use of four dengue virus antigens for determination of dengue immune status by enzyme-linked immunosorbent assay of immunoglobulin G avidity. J Clin Microbiol. 2005 Nov;43(11):5784-6. |
| Pathogenesis: |
|
13749. Helt
AM, Harris E. S-phase-dependent enhancement of dengue virus 2
replication in mosquito cells, but not in human cells.
J Virol. 2005 Nov;79(21):13218-30. 13750.
Owais M, Gupta CM. Targeted drug delivery to macrophages in
parasitic infections. Curr Drug Deliv. 2005 Oct;2(4):311-8. Review. 13751.
Salda LT, Parquet MD, Matias RR, Natividad FF, Kobayashi N,
Morita K. Molecular epidemiology of dengue 2 viruses in the Philippines:
genotype shift and local evolution. Am J Trop Med Hyg. 2005
Oct;73(4):796-802. Vaccines: 13752.
Pugachev KV, Guirakhoo F, Monath TP. New developments in
flavivirus vaccines with special attention to yellow fever. Curr Opin
Infect Dis. 2005 Oct;18(5):387-94. Review. Therapy: 13753.
Mani TR, Arunachalam N, Rajendran R, Satyanarayana K, Dash AP.
Efficacy of thermal fog application of deltacide, a synergized mixture
of pyrethroids, against Aedes aegypti, the vector of dengue. Trop Med
Int Health. 2005 Dec;10(12):1298-304. 13754. Zinderman CE, Wise R, Landow L. Fluid solutions in dengue shock syndrome. N Engl J Med. 2005 Dec 8;353(23):2510-1; |